Cidara Therapeutics Enters Material Definitive Agreement

TL;DR

Cidara Therapeutics signed a big deal, filing an 8-K on Nov 13, 2025.

AI Summary

Cidara Therapeutics, Inc. announced on November 13, 2025, that it has entered into a material definitive agreement. The filing also includes information regarding Regulation FD disclosure and financial statements and exhibits. The company, formerly known as K2 Therapeutics, Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing indicates a significant new contract or partnership for Cidara Therapeutics, which could impact its future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can carry inherent risks related to the terms, obligations, and potential outcomes of the agreement.

Key Players & Entities

• Cidara Therapeutics, Inc. (company) — Registrant
• K2 Therapeutics, Inc. (company) — Former Company Name
• November 13, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• San Diego, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, Par Value $0.0001 Per Share CDTX The Nasdaq Stock Mar
• $221.50 — (the " Common Shares "), at a price of $221.50 per Common Share (the " Common Share Of
• $15,505.00 — Shares, the " Shares "), at a price of $15,505.00 per Series A Share (the " Series A Offe
• $300,563,308.00 — ation fee of an amount in cash equal to $300,563,308.00. Any such termination of the Merger Agr
• $462,405,090.00 — he Company a reverse termination fee of $462,405,090.00 in the event the Merger Agreement is te

Filing Documents

• d59851d8k.htm (8-K) — 54KB
• d59851dex21.htm (EX-2.1) — 523KB
• d59851dex101.htm (EX-10.1) — 54KB
• d59851dex991.htm (EX-99.1) — 28KB
• g46394dsp1a.jpg (GRAPHIC) — 7KB
• g46394dsp1b.jpg (GRAPHIC) — 7KB
• 0001193125-25-281676.txt ( ) — 953KB
• cdtx-20251113.xsd (EX-101.SCH) — 3KB
• cdtx-20251113_lab.xml (EX-101.LAB) — 18KB
• cdtx-20251113_pre.xml (EX-101.PRE) — 11KB
• d59851d8k_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 2.1* Agreement and Plan of Merger, dated as of November 13, 2025, by and among Cidara Therapeutics, Inc., Merck Sharp & Dohme LLC and Caymus Purchaser, Inc. 10.1 Form of Tender and Support Agreement 99.1 Joint press release issued by Merck & Co., Inc. and Cidara Therapeutics, Inc., dated November 14, 2025 104 Cover Page Interactive Date File (embedded within the Inline XBRL document) * Schedules omitted pursuant to Item 601 of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. Additional Information about the Tender Offer and Where to Find It The Offer described in this communication has not yet commenced. This communication is for information purposes only and is neither an offer to buy nor a solicitation of an offer to sell any securities of Cidara. The solicitation and the offer to buy securities of Cidara will only be made pursuant to tender offer materials that Parent and Purchaser will file with the SEC. The solicitation of the offer to buy Cidara Shares will only be made pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related material that Cidara intends to file with the SEC. Cidara will also file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Offer. Once filed, investors will be able to obtain the tender offer statement on Schedule TO, the offer to purchase and the Solicitation/Recommendation Statement of Cidara on Schedule 14D-9 and related materials with respect to the tender offer and the Merger free of charge at the website of the SEC at www.sec.gov or from the information agent named in the tender offer materials. Investors may also obtain, at no charge, the documents filed with or furnished to the SEC by Cidara under the "Investors" section of Cidara's website at www.cidar

Forward-Looking Statements

Forward-Looking Statements Certain statements either contained in or incorporated by reference into this document, other than purely historical information, including statements relating to the sale of Cidara and any statements relating to Cidara's business and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements." These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Such forward-looking statements include those relating to the ability to complete and the timing of completion of the transactions contemplated by Merger Agreement including the parties' ability to satisfy the conditions to the consummation of the tender offer and the other conditions set forth in the Merger Agreement, including the time and benefits thereof, and the possibility of any termination of the Merger Agreement, other 4

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cidara Therapeutics, Inc. Date: November 14, 2025 By: /s/ Jeffrey Stein, Ph.D. Jeffrey Stein, Ph.D. President and Chief Executive Officer 6

View Full Filing

View this 8-K filing on SEC EDGAR